 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| BMS-986406 / BMS
Trial completion, Enrollment change, Combination therapy, Monotherapy, Metastases: A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors (clinicaltrials.gov) - Sep 25, 2024
P1, N=77, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed | N=154 --> 77
- || BMS-986406 / BMS
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors (clinicaltrials.gov) - May 29, 2024
P1, N=154, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed | N=154 --> 77 Trial completion date: Jul 2026 --> Jul 2024 | Trial primary completion date: Apr 2026 --> Jul 2024
- || BMS-986406 / BMS
Enrollment closed, Combination therapy, Monotherapy, Metastases: A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors (clinicaltrials.gov) - May 7, 2024
P1, N=154, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Jul 2026 --> Jul 2024 | Trial primary completion date: Apr 2026 --> Jul 2024 Recruiting --> Active, not recruiting
- || BMS-986406 / BMS
Enrollment change, Combination therapy, Monotherapy, Metastases: A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors (clinicaltrials.gov) - May 16, 2023
P1, N=154, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting N=112 --> 154
- ||| BMS-986406 / BMS
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors (clinicaltrials.gov) - Jun 30, 2022
P1, N=112, Recruiting, Sponsor: Bristol-Myers Squibb
N=112 --> 154 Not yet recruiting --> Recruiting | Trial completion date: Sep 2025 --> Jul 2026 | Trial primary completion date: Mar 2024 --> Apr 2026
- ||| BMS-986406 / BMS
New P1 trial, Combination therapy, Monotherapy, Metastases: A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors (clinicaltrials.gov) - Mar 27, 2022
P1, N=112, Not yet recruiting, Sponsor: Bristol-Myers Squibb